Placeholder Banner

Biden's Executive Order to Advance Biotechnology, Biomanufacturing Prioritizes Science to Solve Global Challenges

September 12, 2022
Media Contact
Lynne Headshot

Dr. Michelle McMurry-Heath, president & CEO of the Biotechnology Innovation Organization, released the following statement in response to the Biden Administration’s “Advancing Biotechnology and Biomanufacturing” Executive Order:

“BIO welcomes the Biden Administration’s directives to strengthen our domestic biotechnology and biomanufacturing industry. This Executive Order the president signed today acknowledges the ‘power of biotechnology’ and its benefits to the U.S. economy, work force and quality of life, as well its potential to boost food and agriculture innovation and address the climate crisis. We commend the administration for launching this initiative, particularly the actions to streamline regulatory regulations for biotechnology products, expand market opportunities for biobased products, work for international alignment of regulatory standards, and invest in training and education pathways to ensure an adequate, diverse biotech workforce.

“From the onset of the Biden administration, BIO has called on the administration to proactively advance biotechnology to foster resiliency and sustainability throughout the agricultural value chain and build a stronger, more resilient, and environmentally sustainable economy. This executive order will help the U.S. and the world meet our environmental and public health goals.”

Background

The following are examples of BIO’s calls to advance biotechnology and biomanufacturing:

###

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…